Unravelling HIV-1's Immune Evasion: Insights into Persistent Infection, Disease Progression, and Emerging Therapies.

HIV remains a significant global public health challenge, with vulnerable populations in regions such as Sub-Saharan Africa, Asia, Eastern Europe, and Latin America bearing a disproportionate burden. This paper explores the latest research on HIV-1's immune evasion strategies, its impact on disease progression, and emerging therapies aimed at finding a cure. Despite advancements in treatment, including antiretroviral therapy (ART) and fixed-dose combination therapies that have made HIV a manageable chronic condition, the virus persists, especially in macrophages, which serve as key reservoirs of infection. HIV-1’s pathogenesis is further complicated by its ability to evade the immune system through immune activation, viral evolution, and coreceptor usage, with distinct strains (R5 and X4) influencing disease progression. Macrophages play a critical role in viral replication, contributing to HIV persistence, particularly in the brain and lymph nodes, which can lead to complications such as AIDS-related dementia. Recent research has provided valuable insights into the role of chemokine receptors like CCR5 and CXCR4 in HIV infection, as well as the CCR5 delta32 mutation, which has helped to enhance our understanding of HIV resistance and progression. The virus’s rapid mutation and immune evasion mechanisms continue to pose significant challenges in developing vaccines or achieving a cure. Additionally, the COVID-19 pandemic has disrupted HIV care, delaying testing, and treatment initiation, and complicating ART adherence, particularly for vulnerable populations . However, the integration of HIV and COVID-19 responses, along with innovations in telehealth and digital interventions, offers opportunities for new healthcare models.